Often times it is. With the efficacy and safety data that was shown in the Phase II trial, this should get through Phase III with no trouble. The fact that patients reported being satisfied with Insugin due to it being easy to use is a huge plus too. This is some of the most positive trial results I have seen and to think that this stock is currently below a penny is insane.
News 
Market Data 
Discover 
